Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • November 6, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6. Erratum for: Sci Rep. 2022 Sep 2;12(1):15013. PMID: 36333397; PMCID: PMC9636406.

Tags: General Internal Medicine, Publications

Domestic violence laws and women’s unmet need for family planning: Quasi-experimental evidence from Africa

Bhuwania P, Raub A, Sprague A, Martin A, Bose B, Kidman R, Heymann J. Domestic violence laws and women's unmet need for family planning: Quasi-experimental[...]

The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari[...]

Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism: A Target Trial Emulation

Watanabe A, Kuno T, Miyamoto Y, Ueyama HA, Gotanda H, Bangalore S, Tsugawa Y. Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism: A Target[...]